1. Introduction {#sec1}
===============

Alzheimer\'s disease (AD) is characterized by amyloid deposition in senile plaques that are mainly composed of 40- and 42-mer amyloid *β*-proteins (A*β*40 and A*β*42) \[[@B1], [@B2]\]. These proteins are secreted from amyloid precursor protein (APP) by two proteases, *β*- and *γ*-secretases \[[@B3]\]. A*β*42 plays a more critical role in the pathogenesis of AD than A*β*40 because of its stronger aggregative ability and neurotoxicity \[[@B3]\]. Oxidative stress is believed to contribute to neuronal loss in AD \[[@B4]--[@B6]\]; one of the proposed mechanisms of A*β*42-induced neurotoxicity is related to the radicalization at both Tyr10 and Met35 accompanied by the generation of hydrogen peroxide \[[@B7], [@B8]\]. On the other hand, soluble oligomeric assembly of A*β* causes cognitive impairment and synaptic dysfunction in AD \[[@B9], [@B10]\].

Our previous investigation using solid-state NMR together with systematic proline replacement proposed a toxic conformer with a turn at positions 22 and 23 in A*β*42 aggregates and a nontoxic conformer with a turn at positions 25 and 26; the former showed a potent ability to aggregate, form oligomers, and exhibit neurotoxicity \[[@B11]\]. The turn formation at positions 22 and 23 along with the neighboring *β*-sheet structure in the toxic conformer of A*β*42 brought Tyr10 and Met35 close together to generate the *S*-oxidized radical cation at Met35, the ultimate toxic radical species, through oxidation by the phenoxy radical at Tyr10 produced by redox reactions \[[@B7], [@B12]\]. The mutations of A*β* are concentrated at positions 21, 22, and 23; A21G (Flemish), E22G (Arctic), E22Q (Dutch), E22K (Italian), and D23N (Iowa) types. These mutations may play a pathological role in cerebral amyloid angiopathy (CAA) or familial AD (FAD) because these mutant proteins induced neuronal death *in vitro* more potently than wild-type A*β*42 \[[@B13]\]. Thus, Glu22 and Asp23 in A*β* are considered to be key residues for neurotoxicity through the formation of radicals.

Recently, Mori and coworkers reported that a novel mutation, in which the Glu-22 residue is defective (E22Δ), induced AD-type dementia without amyloid deposition, and that *in vitro* E22Δ-A*β*42 favorably formed low-molecular weight oligomers to inhibit long-term potentiation (LTP) compared with A*β*42 \[[@B14]\] and to induce synaptic alteration \[[@B15]\]. Therefore, the effects of the deletion at Glu22 on the secondary structure, formation of radicals, and neurotoxicity are interesting from the standpoint of discussing the role of the Glu-22 residue of A*β*42 in the pathogenesis of AD.

This paper describes a comprehensive study of the aggregative ability, secondary structure, radical-generating activity, neurotoxicity in primary rat cortical neuronal cell cultures, and the inhibitory activity of LTP of both E22Δ-A*β*40 and E22Δ-A*β*42. These results were compared with those of E22P-A*β*42 with a turn at positions 22 and 23.

2. Materials and Methods {#sec2}
========================

2.1. Preparation of E22Δ-A*β* {#sec2.1}
-----------------------------

E22Δ-A*β*40 and E22Δ-A*β*42 were synthesized by the method reported previously \[[@B16]\]. Their molecular weights were confirmed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS): E22Δ-A*β*40 (*m/z*: calcd: 4201.76; found: 4201.56 \[M + H\]^+^), E22Δ-A*β*42 (*m/z*: calcd: 4386.00; found: 4385.98 \[M + H\]^+^).

2.2. Sedimentation Assay {#sec2.2}
------------------------

The aggregation kinetics of each A*β* (25 *μ*M) was estimated with the sedimentation assay using HPLC. The experimental procedure was described elsewhere \[[@B13]\]. The area of absorption at 220 nm was integrated and expressed as a percentage of the control.

2.3. Thioflavin T (Th-T) Fluorescence Assay {#sec2.3}
-------------------------------------------

Aggregative ability of each A*β* (25 *μ*M) was evaluated by the Th-T method developed by Naiki and Gejyo \[[@B17]\]. The measurement was performed on a Multidetection Microplate Reader powerscan HT (Dainippon Sumitomo Pharma) at room temperature, as described elsewhere \[[@B13]\]. Fluorescence intensity was measured at 450 nm excitation and 482 nm emission.

2.4. Western Blotting {#sec2.4}
---------------------

Gel electrophoresis using 10--20% Tricine gel (Invitrogen, Carlsbad, CA) and Western blots analysis were carried out according to the manufacturer\'s protocol. The experimental procedure was described elsewhere \[[@B12]\]. Briefly, each A*β* was dissolved in 0.1% NH~4~OH at 250 *μ*M. After a 10-fold dilution by 50 mM sodium phosphate containing 100 mM NaCl at pH 7.4, the resultant peptide solution (25 *μ*M) was incubated for 0, 2, or 4 hr at 37°C. The anti-N-terminus of A*β* antibody, 82E1, (Immuno-Biological Laboratories Co., Ltd., Gunma, Japan) was used at 1 *μ*g/mL as the primary antibody.

2.5. CD Spectrometry {#sec2.5}
--------------------

Each A*β* was dissolved in 0.1% NH~4~OH at 250 *μ*M and diluted 10 times with 50 mM phosphate buffer (pH 7.12). The procedure was described elsewhere \[[@B16]\].

2.6. ESR Spectrometry {#sec2.6}
---------------------

A reliable method for estimating the ability of A*β* (100 *μ*M) to produce radicals using ESR was developed by Butterfield\'s group \[[@B18]\]. ESR spectrometry was performed on an EMX ESR spectrometer (Bruker BioSpin K.K., Karlsruhe, Germany) at room temperature, as described elsewhere \[[@B19]\].

2.7. Estimation of Cell Survival {#sec2.7}
--------------------------------

To evaluate the neurotoxicity of A*β* using an MTT assay, we used undifferentiated PC12 cells, which have the potential to differentiate into neural cells, are sensitive to A*β*, and are generally used for detecting neurotoxicity as a neurotoxicity model \[[@B20]\]. The experimental procedure was described elsewhere \[[@B15]\].

2.8. Preparation of Primary Culture and Estimation of Cell Survival {#sec2.8}
-------------------------------------------------------------------

Near-pure neuronal cultures were obtained from the cerebral cortices of fetal rats (17--19 days of gestation) as described \[[@B21], [@B22]\]. Cultures were maintained in Eagle\'s MEM supplemented with 10% heat-inactivated fetal bovine serum or 10% heat-inactivated horse serum at 37°C in a humidified 5% CO~2~ atmosphere. To prevent the proliferation of nonneural cells, 10 *μ*M cytosine *β*-arabinofuranoside hydrochloride was added after 5 days of plating. In all experiments mature cells used after 11--13 days *in vitro*. Animals were treated in accordance with the guidelines of the Kyoto University animal experimentation committee and the guidelines of the Japanese Pharmacological Society.

Each A*β* was dissolved in 0.02% NH~4~OH at 200 *μ*M and diluted on ice immediately before treatment. After 48 hr treatment, neurotoxicity was evaluated by lactate dehydrogenase (LDH) release assay and MTT assay.

2.9. Long-Term Potentiation {#sec2.9}
---------------------------

Field excitatory postsynaptic potentials (fEPSPs) were recorded from the CA1 region of rat hippocampal slices (Wistar rats, male, 6 weeks old) by electrically stimulating the Schaffer collateral \[[@B23]\]. Hippocampal slices were soaked in E22Δ-A*β*40, E22Δ-A*β*42, and E22P-A*β*42 solution \[20 *μ*g/200 mL phosphate-buffered saline (PBS)\] before high-frequency stimulation (5 trains consisted of four 100-Hz pulses with an intertrain interval of 200 ms). fEPSPs were measured in the presence and absence of each A*β*.

3. Results and Discussion {#sec3}
=========================

3.1. Aggregative Ability of E22Δ Mutants {#sec3.1}
----------------------------------------

E22Δ-A*β*40 and E22Δ-A*β*42 were examined for their aggregative ability by a sedimentation assay: HPLC analysis after centrifugation of each A*β* solution. Both E22Δ-A*β*40 and E22Δ-A*β*42 aggregated at a velocity similar to A*β*42, while A*β*40 hardly aggregated even after 24-hr incubation ([Figure 1(a)](#fig1){ref-type="fig"}). This suggests that the ability to form aggregates of both E22Δ-A*β*40 and E22Δ-A*β*42 would be comparable to that of A*β*42 though soluble A*β* assemblies (oligomers) could not be distinguished from high-molecular weight fibrils in this assay condition (centrifugation: 20,000 g × 10 min). In the Th-T assay, which can estimate the *β*-sheet structure in A*β* aggregates \[[@B17]\], E22Δ-A*β*40 showed higher fluorescence than A*β*40. In contrast, the maximum fluorescence of E22Δ-A*β*42 did not exceed that of A*β*42, although the velocity of E22Δ-A*β*42 showing fluorescence was slightly higher than that of A*β*42 ([Figure 1(b)](#fig1){ref-type="fig"}). These data suggest that the E22Δ mutation accelerates the aggregation of A*β*.

Western blotting was carried out to estimate accurately the oligomerization state of A*β*. E22Δ-A*β*42 formed trimers exclusively, but E22Δ-A*β*40 produced dimers immediately after incubation ([Figure 1(c)](#fig1){ref-type="fig"}), as did the cases in the paper by Tomiyama et al. \[[@B14]\]; however, our Th-T assay results do not coincide with their results \[[@B14]\]; under Tomiyama\'s conditions, both mutants showed almost no fluorescence, even after 7 days. This discrepancy of the Th-T test may be due to the different conditions to make aggregates, presumably resulting in the generation of oligomers containing a *β*-sheet structure, as Ishii and coworkers suggested \[[@B24], [@B25]\].

3.2. Secondary Structure of E22Δ Mutants {#sec3.2}
----------------------------------------

To investigate the secondary structure of E22Δ-A*β*40 and E22Δ-A*β*42, their CD spectra were measured. In the control experiment using A*β*42 ([Figure 2(c)](#fig2){ref-type="fig"}), the positive peak at 200 nm and the negative peak at 220 nm gradually increased during the 48-hr incubation, suggesting that transformation of the random organization into a *β*-sheet structure occurred, while A*β*40 remained mainly random ([Figure 2(a)](#fig2){ref-type="fig"}). In contrast, E22Δ-A*β*42 formed a *β*-sheet-rich structure immediately after dissolution ([Figure 2(d)](#fig2){ref-type="fig"}). The velocity of the transformation of E22Δ-A*β*40 was also higher than that of A*β*42 ([Figure 2(b)](#fig2){ref-type="fig"}). These results suggest that the E22Δ mutation induces *β*-sheet transformation to form A*β* oligomers under our condition.

3.3. Radical Production by E22Δ Mutants {#sec3.3}
---------------------------------------

Our previous studies suggested that the radical productivity of A*β*42 mutants at position 22 such as E22P-, E22K-, E22Q-, and E22G-A*β*42 correlated with their aggregative ability and neurotoxicity \[[@B7]\]. To investigate the effect of E22Δ mutation in A*β*s on the radical-generating activity, ESR was measured using phenyl-*N*-*tert*-butylnitrone (PBN) as a spin-trapping reagent ([Figure 3](#fig3){ref-type="fig"}). ESR signals of E22Δ-A*β*40 were twice more potent than those of A*β*40, and E22Δ-A*β*42 also showed slightly stronger signals than A*β*42. The radical productivity of the E22Δ-A*β*s correlated basically with their ability to form oligomers and a *β*-sheet structure (Figures [1(c)](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}).

3.4. Neurotoxicity of E22Δ-A*β*s in Primary Rat Cortical Neuronal Cell Cultures {#sec3.4}
-------------------------------------------------------------------------------

Having demonstrated that E22Δ mutation enhanced the *β*-sheet structure and radical productivity, we assessed the effect of this mutation on the neurotoxicity in primary rat cortical neuronal cell cultures by LDH and MTT assay ([Figure 4](#fig4){ref-type="fig"}). Treatment of the neurons with 1--20 *μ*M of wild-type A*β*42 for 2 days induced neurotoxicity in a dose-dependent manner in the LDH test ([Figure 4(a)](#fig4){ref-type="fig"}, left), in which the released LDH of the damaged cells (mainly neurons) was measured in the medium. E22P-A*β*42 with a turn at positions 22, and 23 induced stronger damage to the neurons than wild-type A*β*42; cell viability was less 40% at 20 *μ*M ([Figure 4(a)](#fig4){ref-type="fig"}, right). On the other hand, the difference in cell viability between the vehicle and wild-type A*β*42 did not reach a significant level in the MTT assay even at 20 *μ*M ([Figure 4(b)](#fig4){ref-type="fig"}, left). The cell viability of E22P-A*β*42 in MTT was also about 50% at 20 *μ*M. In the MTT assay, total cells containing neurons, astrocytes, and microglia damaged by A*β*s were counted. Since the neurons are more sensitive to damage than astrocytes or microglia in the primary cell cultures \[[@B26]\], the "neurotoxicity" estimated by the LDH test is often stronger than that evaluated by the MTT test.

It is worth noting that E22Δ-A*β*40 and E22Δ-A*β*42 as well as A*β*40 at 20 *μ*M failed to show neurotoxicity against the primary cultures both in the LDH and MTT tests ([Figure 4](#fig4){ref-type="fig"}). These results are consistent with those reported by Takuma et al.; the neurotoxicity of E22Δ-A*β*42 was very weak against mouse neuroblastoma Neuro-2a and human neuroblastoma IMR-32 \[[@B15]\]. In our MTT test using rat neuroblastoma PC12 cells, the IC~50~ of E22Δ-A*β*42 and wild-type A*β*42 was 4.6 ± 1.1 *μ*M and 0.65 ± 0.11 *μ*M, respectively, showing that E22Δ-A*β*42 was significantly less toxic than wild-type A*β*42. The neurotoxicity of E22Δ-A*β*40 (IC~50~ = 10 ± 1.0 *μ*M) was weak as expected, but slightly stronger than that of A*β*40 (IC~50~ = 20 ± 1.0 *μ*M).

3.5. Synaptotoxicity of E22Δ Mutants {#sec3.5}
------------------------------------

Selkoe and coworkers suggested that A*β* dimers are the smallest synaptotoxic species inhibiting the LTP in the pathogenesis of AD and that plaque cores are largely inactive but sequester and release dimers \[[@B27]\]. Tomiyama et al. reported the more potent inhibition of LTP by E22Δ-A*β*42 than by wild-type A*β*42 \[[@B14]\]. We tested the inhibition of LTP by E22Δ-A*β*40 using rat hippocampal slices. [Figure 5](#fig5){ref-type="fig"} shows that E22Δ-A*β*40 is not such a potent inhibitor of LTP as E22Δ-A*β*42, whose inhibitory potency was stronger that of than wild-type A*β*42, as Tomiyama et al. reported \[[@B14]\]. This coincides with the previous datas that the 42-mer A*β* showed more potent neurotoxicity than 40-mer A*β* \[[@B13]\]. Notably, E22P-A*β*42, which can more readily form a toxic conformer with a turn at positions 22 and 23 than wild-type A*β*42 \[[@B11]\], inhibited the LTP more strongly than E22Δ-A*β*42 at an almost undetectable level after 60 min ([Figure 5(b)](#fig5){ref-type="fig"}). This suggests that the conformation at positions 22 and 23 of E22P-A*β*42 might be similar to that of E22Δ-A*β*42 at positions 21 and 23.

3.6. Relevance of E22Δ Mutation to Turn-Induced Neurotoxicity {#sec3.6}
-------------------------------------------------------------

The present results suggest that E22Δ mutation in A*β* accelerates the transformation of a random form into a *β*-sheet structure ([Figure 2](#fig2){ref-type="fig"}) and radical productivity ([Figure 3](#fig3){ref-type="fig"}) but does not increase neurotoxicity in primary rat cortical neuronal cell cultures ([Figure 4](#fig4){ref-type="fig"}). E22Δ-A*β*42 synthesized in our laboratory showed the significant formation of oligomers ([Figure 1](#fig1){ref-type="fig"}) and synaptotoxicity ([Figure 5](#fig5){ref-type="fig"}), as reported by Mori and coworkers \[[@B14]\]. In addition, E22P-A*β*42 inhibited LTP more severely than E22Δ-A*β*42 ([Figure 5](#fig5){ref-type="fig"}). We previously reported that E22P-A*β*42, with a turn at positions 22 and 23 as a Pro-X corner (X: variable amino acid residue) \[[@B28]\], could form significant oligomers \[[@B11]\] with a *β*-sheet-rich structure \[[@B16]\] and radicals to result in potent neurotoxicity with the formation of radicals \[[@B7]\]; therefore, E22Δ-induced synaptotoxicity might be in part related to turn-induced radical formation. This implies that conformational change in E22Δ-A*β* is similar to that in E22P-A*β*42, but is not the same since E22Δ-A*β*42 exhibited no neurotoxicity, unlike E22P-A*β*42 and wild-type A*β*42.

It should be noted that the effects of E22Δ mutation on the physicochemical properties of A*β*40 are significantly higher than those of A*β*42. This tendency is similar to cases of other CAA or FAD mutant A*β*s. We previously reported a comprehensive study on the aggregation, neurotoxicity, and secondary structure of A*β* mutants at positions 21--23 (A21G, E22G, E22Q, E22K, and D23N) \[[@B13]\]. Since A*β*40 is secreted in neurons about nine times more abundantly than A*β*42 \[[@B3]\], in some cases A*β*40 may play a critical role in the pathogenesis of CAA or FAD. In addition, the E22Δ mutant of A*β*40 \[[@B14]\] as well as the CAA- or FAD-related A*β*40 mutants at positions 21, 22, and 23 have been reported to be more resistant than wild-type A*β*40 against degradation by insulin-degrading enzyme \[[@B29]\]; however, it remains controversial whether E22Δ is a familial type of AD or AD-type dementia.

Mori, Tomiyama, and coworkers implied the intracellular accumulation of A*β* oligomers using cultured cells \[[@B30]\] and their own developed mouse model \[[@B31]\] with E22Δ mutation. This mutation also caused apoptosis induced by stress in the endoplasmic reticulum \[[@B30]\]. Quite recently, we proposed the involvement of a turn at positions 22 and 23 of A*β* in intracellular amyloidosis \[[@B32]\]. Thus, the increase of radical productivity by E22Δ mutation is in good agreement with the turn-induced oxidative stress of A*β*42 \[[@B7]\], presumably *via* the interplay between Tyr10 and Met35 \[[@B12]\]. The deletion mutation of the residue at position 22 might promote Tyr10 in close proximity to the sulfur atom of Met35, inducing the effective production of radicals.

4. Conclusion {#sec4}
=============

In summary, E22Δ-A*β*42 effectively induced the transformation of a random form to a *β*-sheet structure and the formation of radicals accompanied with oligomerization. However, the molecular mechanism of the pathology of AD of E22Δ-A*β*42 might be different from that of wild-type A*β*42 since E22Δ-A*β*42 showed more potent synaptotoxicity but weaker neurotoxicity than wild-type A*β*42.
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![Aggregation profiles of E22Δ-A*β*40 and E22Δ-A*β*42 (25 *μ*M) after incubation at 37°C. (a) Sedimentation assay estimated by HPLC analysis after centrifugation. (b) Th-T fluorescence assay. °, A*β*42; △, A*β*40; ●, E22Δ-A*β*42; ▲, E22Δ-A*β*40. (c) Western blotting without incubation.](IJAD2011-431320.001){#fig1}

![CD spectra of E22Δ-A*β*40 and E22Δ-A*β*42 (25 *μ*M). (a) A*β*40, (b) E22Δ-A*β*40, (c) A*β*42, (d) E22Δ-A*β*42. Each A*β* (25 *μ*M) was incubated in phosphate buffer at 37°C for the following times: □, 0 h; ▲, 4 h; △, 8 h; °, 24 h; ■, 48 h.](IJAD2011-431320.002){#fig2}

![ESR spectra of E22Δ-A*β*40 and E22Δ-A*β*42 (100 *μ*M) after 48-hr incubation at 37°C. (a) A*β*40, (b) E22Δ-A*β*40, (c) A*β*42, (d) E22Δ-A*β*42. The spectra of A*β* are shown after subtraction of the background spectrum in the presence of PBN without A*β*. Numbers in parentheses represent relative integral intensities of ESR signals, where the intensity of A*β*40 was taken as 1.0.](IJAD2011-431320.003){#fig3}

![Neurotoxicity of A*β*40, A*β*42, E22Δ-A*β*40, E22Δ-A*β*42, and E22P-A*β*42 with the indicated concentration (1, 2, 5, 10, and 20 *μ*M) using primary rat cortical neuronal cell cultures after 48-hr incubation at 37°C. Data are expressed as the mean ± s.e.m. \**P* \< .05 *versus* vehicle, \*\**P* \< .01*versus* vehicle. Veh: vehicle.](IJAD2011-431320.004){#fig4}

![*In vivo* synaptotoxicity of E22Δ-A*β*40, E22Δ-A*β*42, and E22P-A*β*42 estimated by LTP expression. (a) Field excitatory postsynaptic potentials (fEPSPs) were recorded from the CA1 region of rat hippocampal slices (Wistar rats, male, 6 weeks old) by delivering theta burst stimulation (TBS) to the Schaffer collateral/commissural pathway. LTP was induced by high-frequency stimulation (5 trains consisted of four 100-Hz pulses with an intertrain interval of 200 ms) in the presence and absence of each A*β* (20 *μ*g/200 mL PBS), to be injected into the lateral ventricle 20 min before stimulation. Each point on the graph represents the mean ± s.e.m. of basal fEPSP slope (0 min); *n* = 12 for PBS, *n* = 9 for E22Δ-A*β*40, *n* = 10 for E22Δ-A*β*42, and *n* = 10 for E22P-A*β*40. \**P* \< .0001 versus PBS; *P* = .4258 between PBS and E22Δ-A*β*40. *P* \< .0001 versus PBS, when fEPSP slopes were compared with 1 to 60 min after TBS. The means between the four groups were compared using analysis of variance followed by Fisher\'s protected least significant difference (PLSD) test. °, PBS; ●, E22Δ-A*β*40; ▲, E22Δ-A*β*42; △, E22P-A*β*42. (b) Typical field excitatory postsynaptic potentials at (1) 0 and (2) 60 minutes after TBS.](IJAD2011-431320.005){#fig5}

[^1]: Academic Editor: Katsuhiko Yanagisawa
